SUSMITA SAKRUTI M.D NPI 1346553187

NPI Information

  • NPI: 1346553187
  • Provider Name: SUSMITA SAKRUTI, M.D
  • Classification: Internal Medicine - 207RH0003X
  • Specialization: Hematology & Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 5125 TEXOMA MEDICAL CENTER DR STE 100
    DENISON, TX
    ZIP 75020
  • Phone: (903) 868-4700

Map and Directions

Get Directions

NPI Details

Susmita Sakruti, M.D is a hematology and oncology internal medicine in Denison, TX with 20 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Susmita Sakruti, M.D NPI is 1346553187. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

5125 TEXOMA MEDICAL CENTER DR STE 100
DENISON, TX
ZIP 75020-084
Phone: (903) 868-4700

The NPI 1346553187 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
  • Injection, nivolumab, 1 mg (HCPCS:J9299)
  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
  • Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
  • Injection, denosumab, 1 mg (HCPCS:J0897)
  • Insertion of needle into vein for collection of blood sample (HCPCS:36415)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • Injection, fluorouracil, 500 mg (HCPCS:J9190)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
  • Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
  • Blood test, comprehensive group of blood chemicals (HCPCS:80053)
  • Injection, irinotecan, 20 mg (HCPCS:J9206)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Injection, carboplatin, 50 mg (HCPCS:J9045)
  • Blood creatinine level (HCPCS:82565)
  • Iron level (HCPCS:83540)
  • Iron binding capacity (HCPCS:83550)
  • Ferritin (blood protein) level (HCPCS:82728)
  • Injection, zoledronic acid, 1 mg (HCPCS:J3489)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Lactate dehydrogenase (enzyme) level (HCPCS:83615)
  • Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
  • Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Psa (prostate specific antigen) measurement, total (HCPCS:84153)
  • Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
  • Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
  • Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
  • Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
  • Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
  • Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
  • Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
  • Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session (HCPCS:G6015)
  • Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
  • Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
  • Irrigation of implanted venous access drug delivery device (HCPCS:96523)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Ct scan of chest with contrast (HCPCS:71260)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
  • Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
  • Unclassified drugs (HCPCS:J3490)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
  • Nuclear medicine study whole body with ct scan (HCPCS:78816)
  • Ct scan of chest without contrast (HCPCS:71250)
  • Injection of drug or substance into vein (HCPCS:96374)
  • Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)

The enumeration date for this NPI number is 7/21/2010 and was last updated on 9/21/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RX0202XInternal MedicineMedical OncologyR8091TEXASNo
2207RH0003XInternal MedicineHematology & OncologyR8091TEXASYes
3207RH0003XInternal MedicineHematology & OncologyA161532CALIFORNIANo

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.